Clinical Trial Update: Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma

View source ↗

Summary

Expanded Access Program update for cilta-cel in multiple myeloma noting out-of-specification results observed in participants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Cilta-cel (ciltacabtagene autoleucel)

Snippet

Sponsor: Janssen Scientific Affairs, LLC | Conditions: Multiple Myeloma | Status: AVAILABLE